COMMUNIQUÉS West-GlobeNewswire

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

22/02/2024 - 13:47

Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability. A growing body of evidence supports that activation of more than one [...]

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

22/02/2024 - 13:32

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and [...]

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

22/02/2024 - 13:31

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development [...]

Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update

22/02/2024 - 13:30

Full year 2023 total revenues of $464.4 million , compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product sales were $462.2 million , representing year-over-year growth of 86% . CAPLYTA fourth quarter 2023 [...]

Venus Concept Announces CE Mark for Venus Versa Pro in Europe

22/02/2024 - 13:30

TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received the CE Mark from DEKRA [...]

Kura Oncology to Participate in Three Upcoming Investor Conferences

22/02/2024 - 13:30

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

22/02/2024 - 13:30

WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration (FDA) Granted Priority [...]

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

22/02/2024 - 13:30

Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay Nayak, MBBS, PhD to become [...]

Bitech Technologies Appoints Sid Sung as Its New Chief Innovation Officer to Lead the Digital Revolution in the Renewable Energy Industry

22/02/2024 - 13:30

Newport Beach, CA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bitech Technologies Corporation [ OTCQB: BTTC ], (“the Company” or “Bitech”) a global technology solution provider dedicated to green energy solutions, is delighted [...]

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

22/02/2024 - 13:30

- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on positive results of Phase 3 ATTRibute-CM trial [...]

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

22/02/2024 - 13:30

WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

22/02/2024 - 13:30

On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024 Expect to initiate the Phase 3 study of NTLA-2002 for [...]

InflaRx Appoints Jan Medina as Head of Investor Relations

22/02/2024 - 13:30

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of [...]

The Joint Corp. to Host Conference Call on Thursday, March 7th to Discuss Fourth Quarter and Year-end 2023 Results

22/02/2024 - 13:05

SCOTTSDALE, Ariz., Feb. 22, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, announced it will report its fourth [...]

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

22/02/2024 - 13:01

-- Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024 -- -- Significant unmet need with 5,000 to 8,000 patients [...]

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

22/02/2024 - 13:00

-- Fourth quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothalamic obesity; top- [...]

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

22/02/2024 - 13:00

KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in [...]

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

22/02/2024 - 13:00

DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases [...]

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

22/02/2024 - 13:00

STAMFORD, Conn., Feb. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management [...]